| Autor: |
Lambroia L; Humanitas Research Hospital-IRCCS, 20072 Rozzano, Italy., Conca Dioguardi CM; Human Technopole, 20157 Milan, Italy., Puccio S; Institute of Genetic and Biomedical Research, National Research Council, UoS of Milan, 20072 Milan, Italy.; Laboratory of Translational Immunology and Humanitas Flow Cytometry Core, Humanitas Research Hospital, 20072 Milan, Italy., Pansa A; Upper Gastrointestinal Surgery Unit, IRCCS Humanitas Research Hospital, 20089 Milan, Italy., Alvisi G; Laboratory of Translational Immunology and Humanitas Flow Cytometry Core, Humanitas Research Hospital, 20072 Milan, Italy., Basso G; Genomic Unit, Humanitas Research Hospital, 20072 Milan, Italy., Cibella J; Human Technopole, 20157 Milan, Italy., Colombo FS; Laboratory of Translational Immunology and Humanitas Flow Cytometry Core, Humanitas Research Hospital, 20072 Milan, Italy., Marano S; Upper Gastrointestinal Surgery Unit, IRCCS Humanitas Research Hospital, 20089 Milan, Italy., Basato S; Upper Gastrointestinal Surgery Unit, IRCCS Humanitas Research Hospital, 20089 Milan, Italy., Alfieri R; Upper Gastrointestinal Surgery Unit, IRCCS Humanitas Research Hospital, 20089 Milan, Italy., Giudici S; Upper Gastrointestinal Surgery Unit, IRCCS Humanitas Research Hospital, 20089 Milan, Italy., Castoro C; Upper Gastrointestinal Surgery Unit, IRCCS Humanitas Research Hospital, 20089 Milan, Italy.; Department of Biomedical Sciences, Humanitas University, 20072 Milan, Italy., Peano C; Human Technopole, 20157 Milan, Italy.; Institute of Genetic and Biomedical Research, National Research Council, UoS of Milan, 20072 Milan, Italy. |
| Abstrakt: |
Esophageal cancer is a highly lethal malignancy, representing 5% of all cancer-related deaths. The two main subtypes are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). While most research has focused on ESCC, few studies have analyzed EAC for transcriptional signatures linked to diagnosis or prognosis. In this study, we utilized single-cell RNA sequencing and bulk RNA sequencing to identify specific immune cell types that contribute to anti-tumor responses, as well as differentially expressed genes (DEGs). We have characterized transcriptional signatures, validated against a wide cohort of TCGA patients, that are capable of predicting clinical outcomes and the prognosis of EAC post-surgery with efficacy comparable to the currently accepted prognostic factors. In conclusion, our findings provide insights into the immune landscape and therapeutic targets of EAC, proposing novel immunological biomarkers for predicting prognosis, aiding in patient stratification for post-surgical outcomes, follow-up, and personalized adjuvant therapy decisions. |
